Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

CN16 - Periodontal disease and cancer risk: A nationwide population-based cohort study

Date

16 Sep 2021

Session

ePoster Display

Topics

Cancer Prevention

Tumour Site

Presenters

Chung Hyun Park

Citation

Annals of Oncology (2021) 32 (suppl_5): S1261-S1265. 10.1016/annonc/annonc692

Authors

C.H. Park1, E.H. Kim2, L. Myeongjee2, A. Joong Bae3, S. Sang Jun3, S. Beom3, P. Yu Rang2, J. Inkyung4, H.S. Kim5

Author affiliations

  • 1 Department Of Internal Medicine, Yonsei University, 03722 - Seoul/KR
  • 2 Epartment Of Biomedical Systems Informatics, Yonsei University, Seoul/KR
  • 3 Department Of Internal Medicine, Division Of Medical Oncology, Yonsei University, Seoul/KR
  • 4 Department Of Biostatistic And Computing, Yonsei University, Seoul/KR
  • 5 Medical Oncology, Yonsei University, 03722 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract CN16

Background

Although emerging evidence suggests periodontal disease might increase the risk of cancers, comorbidity and lifestyle behaviors, such as smoking or body mass index (BMI), may have confounded the reported association. This study aimed to investigate whether chronic periodontitis is associated with cancer risk.

Methods

We conducted a population-based retrospective cohort study using the Korean National Health Insurance Cohort Database obtained from January 2003 to December 2015. Among a total of 713,201 participants, 53,075 patients who had a history of periodontitis without a cancer history were selected and followed up for ten years from this cohort. Confounding factors included demographic factors (age, sex. Income, residential area), lifestyle behaviors (smoking history, BMI), comorbidities, defined by Charlson Comorbidity Index (CCI), such as hypertension, diabetes, heart failure, pulmonary disease. Multivariable cox regression analysis was applied to estimate the adjusted hazard ratio (aHR).

Results

Among a total of 713,201 participants, 53,075 patients with periodontitis and 660,126 controls were included in this study. During a 10-year follow-up, overall cancer incidence rates were 6,600 and 2,996 per 100,000 person-years in the periodontitis and control groups, respectively. An increased risk of total cancer was observed for participants with periodontitis, compared to participants without periodontitis, adjusting for age, sex, comorbidities using CCI, BMI, and smoking history (aHR, 1.129; 95% confidence interval [CI], 1.089 to 1.171; P < 0.0001). Organ-specifically, significant associations were found in stomach cancer (aHR, 1.136; 95% CI, 1.042-1.239), colorectal cancer (aHR, 1.129; 95% CI, 1.029-1.239), lung cancer (aHR, 1.127; 95% CI, 1.008-1.260), bladder cancer (aHR, 1.307; 95% CI, 1.071-1.595), thyroid cancer (aHR, 1.191; 95% CI, 1.085-1.308), and leukemia (aHR, 1.394; 95% CI, 1.039-1.872), respectively.

Conclusions

Periodontitis disease was associated with a modest but significantly increased risk of cancer, which persisted after controlling confounding factors. The increased risks suggest that systemic effect of oral inflammation might evade host immune system participating cancer immune surveillance.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This work was supported in part by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2019R1C1C1006709, 2018R1A5A2025079, and 2020M3F7A1094093), a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Korea (KHIDIHI19C1015010020), \"The Alchemist Project\" through the Ministry of Trade, Industry and Energy (MOTIE, Korea) (20012443), and Severance Hospital Research fund for Clinical excellence (SHRC) (C-2020-0032 and C-2020-0025) (H.S.K.)

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.